Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

Home
/
update
/
details

Roche’s VENTANA CLDN18 (43-14A) RxDx Assay for Identifying Gastric and GEJ Cancer Patients Receives CE Mark Approval

NextEdge Admin

11 Oct 2024

2 min 25 sec

Roche has announced that its VENTANA CLDN18 (43-14A) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive CE Mark approval for assessing CLDN18 protein expression in tumors of patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma. This test enables the identification of patients who may be eligible for Astellas’ targeted therapy, VYLOY (zolbetuximab).

“Gastric cancer is a major global health issue, with only three percent of metastatic patients in Europe surviving beyond five years,” said Matt Sause, CEO of Roche Diagnostics. The new companion diagnostic is a significant advancement, as it helps clinicians identify patients who may benefit from targeted treatments, potentially improving outcomes.

Current guidelines emphasize using biomarkers to inform treatment decisions for gastric/GEJ cancer. The VENTANA CLDN18 (43-14A) RxDx Assay evaluates CLDN18.2 status, providing essential information for clinicians regarding the suitability of CLDN18.2 targeted therapies. VYLOY is the first treatment approved for CLDN18.2-positive gastric/GEJ cancer, offering more tailored options for patients.

Gastric cancer is the fifth most common cancer globally, with high incidence rates in Central and Eastern Europe. Often diagnosed late, it has an overall survival rate of just 25% in the EU. The VENTANA assay measures both CLDN18.1 and CLDN18.2 isoforms, with the latter being predominantly expressed in gastric and GEJ cancers. Approval of the assay is based on results from the SPOTLIGHT and GLOW studies, which showed that approximately 38% of patients had high levels of CLDN18, benefiting from the combination of zolbetuximab and chemotherapy.